Reversine: Precision Aurora Kinase Inhibitor for Cancer and Cell Cycle Research

Executive Summary: Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) is a highly selective small molecule inhibitor of Aurora kinases A, B, and C, with respective IC50 values of 150 nM, 500 nM, and 400 nM, enabling targeted disruption of mitotic regulation in cancer models (APExBIO). It is insoluble in water but readily dissolves in DMSO (≥19.65 mg/mL) and ethanol (≥6.69 mg/mL under gentle warming and ultrasonic treatment). Reversine induces dedifferentiation in murine myoblasts and demonstrates anti-proliferative and pro-apoptotic effects in multiple cervical cancer cell lines (HeLa, U14, Siha, Caski, C33A) both in vitro and in vivo. In murine models, Reversine, especially when combined with aspirin, synergistically reduces tumor burden via growth inhibition and apoptosis induction (Kaisaria et al., 2019). The A3760 kit is intended for research use only, not for diagnostic or therapeutic application.

Biological Rationale

Aurora kinases A, B, and C are serine/threonine kinases that orchestrate key steps of mitotic regulation, including centrosome maturation, spindle assembly, and chromosome segregation (Kaisaria et al., 2019). Dysregulation of Aurora kinase activity is implicated in genomic instability and tumorigenesis. The mitotic checkpoint system, which involves the assembly and disassembly of the Mitotic Checkpoint Complex (MCC), ensures accurate chromosome segregation. Polo-like kinase 1 (Plk1) and proteins such as p31^comet play regulatory roles in this checkpoint system. Reversine, as a potent Aurora kinase inhibitor, allows researchers to dissect these mitotic processes with high specificity. Its cell-permeable nature and defined solubility profile make it suitable for both in vitro and in vivo models. By inhibiting Aurora kinases, Reversine disrupts cell cycle checkpoints, offering a validated strategy for cancer cell proliferation inhibition and apoptosis induction.

Mechanism of Action of Reversine

Reversine directly inhibits Aurora kinases A (IC50 = 150 nM), B (IC50 = 500 nM), and C (IC50 = 400 nM) under standard kinase assay conditions (ATP 10 μM, 37°C, pH 7.5) (APExBIO). Aurora kinases phosphorylate key substrates required for mitotic progression, including those involved in centrosome maturation, spindle assembly, and chromosome alignment. Inhibition of these kinases by Reversine leads to aberrant spindle formation, defective chromosome segregation, and activation of mitotic checkpoints. This results in mitotic arrest, polyploidy, and ultimately, induction of apoptosis in susceptible cancer cells. Reversine's structure allows it to fit into the ATP-binding pocket of Aurora kinases, competitively blocking phosphorylation events essential for cell division. In established cancer models, Reversine has been shown to suppress Aurora kinase expression and activity, resulting in reduced proliferation and increased apoptotic markers.

Evidence & Benchmarks

• Reversine exhibits potent inhibition of Aurora kinase A (IC50 = 150 nM), B (IC50 = 500 nM), and C (IC50 = 400 nM) in cell-free kinase assays (APExBIO).
• In vitro, Reversine induces dedifferentiation of murine myoblasts, demonstrating cellular reprogramming capacity (APExBIO).
• Reversine suppresses proliferation and triggers apoptosis in cervical cancer cell lines (HeLa, U14, Siha, Caski, C33A) at concentrations of 1–10 μM, 24–72 h incubation (APExBIO).
• In vivo, Reversine alone or in combination with aspirin reduces tumor weight and volume in murine cervical cancer models (tumor volume reduction >50% vs. control, p < 0.01) (Kaisaria et al., 2019).
• Reversine's inhibition of mitotic kinases disrupts MCC disassembly, providing a tool to dissect checkpoint regulation (see this analysis for advanced mechanisms not covered here).

Applications, Limits & Misconceptions

Applications: Reversine is used to study mitotic regulation, cell cycle checkpoints, and cancer cell proliferation. It is validated in both 2D cell culture and in vivo murine cancer models, particularly cervical cancer. Its ability to induce dedifferentiation makes it relevant for regenerative biology studies as well (see comparison: this article details translational anti-cancer models and benchmarks Reversine's potency).

• Dissection of Aurora kinase signaling pathways in mitosis and oncogenesis.
• High-fidelity inhibition of cell cycle progression and checkpoint function.
• Modeling therapeutic strategies for tumor growth suppression and apoptosis induction.
• Synergistic studies with other agents (e.g., aspirin) in combinatorial cancer therapy.

Common Pitfalls or Misconceptions

• Not for diagnostic or clinical use: Reversine is strictly for research; it is not FDA-approved for therapy (APExBIO).
• Solubility constraints: Ineffective in aqueous buffers; must be dissolved in DMSO or ethanol with specified minimum concentrations and protocols.
• Storage precautions: Solutions are unstable for long-term storage; freshly prepare for each experiment and store solid at -20°C.
• Specificity: While highly selective, off-target effects at supra-physiological concentrations cannot be excluded; always titrate dose-response.
• Cell line/model variability: Efficacy and apoptotic response may vary by cell type and genetic background.

Workflow Integration & Parameters

For optimal results, dissolve Reversine (A3760) in DMSO at ≥19.65 mg/mL or in ethanol at ≥6.69 mg/mL using gentle warming (37°C) and brief sonication. Filter-sterilize if required. Use freshly prepared solutions for cell culture or in vivo administration. Standard working concentrations in cell-based assays range from 0.1–10 μM, depending on endpoint and cell type. Solid should be stored at -20°C in a desiccated environment. Avoid repeated freeze-thaw cycles. For in vivo studies, ensure rigorous experimental controls and ethical compliance. For advanced integration into checkpoint disassembly studies, see this workflow guide; this article provides extended benchmarks and troubleshooting strategies not addressed there.

Conclusion & Outlook

Reversine is a validated, high-potency Aurora kinase inhibitor supporting both fundamental and translational cancer research. Its atomic-level specificity and robust activity profile in cell and animal models make it a key resource for dissecting mitotic regulation and cell cycle checkpoints. APExBIO's A3760 kit offers researchers a rigorously characterized compound with clear guidelines for solubility, storage, and application. Ongoing studies continue to expand Reversine's utility, particularly in combination therapies and advanced checkpoint pathway analysis. For detailed protocols and product support, refer to the official Reversine product page.